

Matthew W Mccarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4049400/publications.pdf>

Version: 2024-02-01

57
papers

1,051
citations

516215
16
h-index

433756
31
g-index

61
all docs

61
docs citations

61
times ranked

1486
citing authors

#	ARTICLE	IF	CITATIONS
1	Ethical challenges of prospective clinical trials during the COVID-19 pandemic. Expert Review of Anti-Infective Therapy, 2022, 20, 549-554.	2.0	1
2	The Diagnostic Accuracy Of Procalcitonin for Urinary Tract Infection in Hospitalized Older Adults: a Prospective Study. Journal of General Internal Medicine, 2022, 37, 3663-3669.	1.3	6
3	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Expert Opinion on Pharmacotherapy, 2022, 23, 623-628.	0.9	5
4	Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections. Drugs in R and D, 2022, 22, 113-117.	1.1	5
5	Pharmacokinetics and Pharmacodynamics of Ibrexafungerp. Drugs in R and D, 2022, 22, 9-13.	1.1	15
6	Fluticasone propionate as a potential treatment for COVID-19. Drugs of Today, 2022, 58, 241-247.	0.7	1
7	Outpatient treatment options to address the SARS-CoV-2 variant Omicron. Expert Review of Anti-Infective Therapy, 2022, 20, 1129-1133.	2.0	8
8	11010 The diagnostic accuracy of procalcitonin for urinary tract infection in hospitalized older adults. Journal of Clinical and Translational Science, 2021, 5, 28-29.	0.3	0
9	Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin. Clinical Pharmacokinetics, 2021, 60, 1387-1394.	1.6	2
10	The Great Gatsby and the challenge of unreliable narrators. Lancet, The, 2021, 398, 203.	6.3	0
11	At-home coronavirus testing: the next game-changer?. Expert Review of Molecular Diagnostics, 2021, 21, 1-2.	1.5	9
12	Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial. Infectious Diseases and Therapy, 2020, 9, 53-67.	1.8	26
13	Procalcitonin utilization in the real world: An observational study of antibiotic prescribing practices. Journal of Evaluation in Clinical Practice, 2020, 26, 1220-1223.	0.9	0
14	Efficacy of Amphotericin B in Corneal Preservation Media After Extended Frozen Storage. Cornea, 2020, 39, 1274-1277.	0.9	4
15	Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine. Expert Review of Anti-Infective Therapy, 2020, 18, 799-805.	2.0	6
16	Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy. Clinical Pharmacokinetics, 2020, 59, 567-573.	1.6	15
17	279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry. Open Forum Infectious Diseases, 2020, 7, S140-S140.	0.4	0
18	The expanding use of matrix-assisted laser desorption/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases. Expert Review of Molecular Diagnostics, 2019, 19, 241-248.	1.5	25

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1149-1153.	1.6	12
20	Teixobactin: a novel anti-infective agent. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 1-3.	2.0	15
21	Frequency of Ethical Issues on a Hospitalist Teaching Service at an Urban, Tertiary Care Center. <i>Journal of Hospital Medicine</i> , 2019, 14, 290-293.	0.7	7
22	The rise of hospitalists: an opportunity for infectious diseases investigators. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 385-389.	2.0	5
23	Cefiderocol: a novel siderophore cephalosporin. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 193-197.	1.9	57
24	The prognostic value of mid-regional pro-adrenomedullin in the evaluation of acute dyspnea. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 147-153.	1.5	3
25	Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1483-1491.	1.6	32
26	Novel applications for serum procalcitonin testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 27-34.	1.5	35
27	The surviving sepsis controversy: a call to action for hospital medicine. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 889-892.	2.0	1
28	Candidemia in the cancer patient: diagnosis, treatment, and future directions. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 849-854.	2.0	14
29	Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 909.	1.8	26
30	Recent Advances in the Treatment of Scedosporiosis and Fusariosis. <i>Journal of Fungi (Basel)</i> , 2019, 5, 302.	1.5	49
31	Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 601-604.	1.5	4
32	Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 229-238.	1.0	10
33	Nucleic acid amplification methodologies for the detection of pulmonary mold infections. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 271-279.	1.5	11
34	Prophylactic Measures During Induction for Acute Myeloid Leukemia. <i>Current Oncology Reports</i> , 2017, 19, 18.	1.8	13
35	Drug development challenges and strategies to address emerging and resistant fungal pathogens. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 577-584.	2.0	38
36	Combination therapy for the treatment of pulmonary mold infections. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 481-489.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Drugs currently under investigation for the treatment of invasive candidiasis. Expert Opinion on Investigational Drugs, 2017, 26, 825-831.	1.9	27
38	Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis. Expert Review of Respiratory Medicine, 2017, 11, 739-748.	1.0	7
39	OUP accepted manuscript. Medical Mycology, 2017, 55, 859-868.	0.3	19
40	Molecular diagnosis of invasive mycoses of the central nervous system. Expert Review of Molecular Diagnostics, 2017, 17, 129-139.	1.5	16
41	Checkpoint inhibitors and the risk of infection. Expert Review of Precision Medicine and Drug Development, 2017, 2, 287-293.	0.4	3
42	The fungal meningitis outbreak five years later: what have we learned about <i>Exserohilum rostratum</i> ?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 321-325.	0.4	0
43	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. Journal of Infectious Diseases, 2017, 216, S474-S483.	1.9	135
44	Harnessing the potential of CRISPR-Cas9 to advance the study of human fungal pathogens. Expert Review of Precision Medicine and Drug Development, 2017, 2, 295-301.	0.4	1
45	Fungal Infections of the Central Nervous System in Children. Journal of the Pediatric Infectious Diseases Society, 2017, 6, e123-e133.	0.6	33
46	Containment strategies to address the expanding threat of multidrug-resistant <i>Candida auris</i> . Expert Review of Anti-Infective Therapy, 2017, 15, 1095-1099.	2.0	8
47	Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	12
48	Future Research Priorities in Fungal Resistance. Journal of Infectious Diseases, 2017, 216, S484-S492.	1.9	26
49	Translational Development and Application of (1 ³ C)- β -D-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses. International Journal of Molecular Sciences, 2017, 18, 1124.	1.8	16
50	Teaching Clinical Ethics at the Bedside: William Osler and the Essential Role of the Hospitalist. AMA Journal of Ethics, 2017, 19, 528-532.	0.4	9
51	The Rise of Hospitalists: An Opportunity for Clinical Ethics. Journal of Clinical Ethics, 2017, 28, 325-332.	0.1	3
52	PCR methodology and applications for the detection of human fungal pathogens. Expert Review of Molecular Diagnostics, 2016, 16, 1025-1036.	1.5	36
53	Emerging diagnostic and therapeutic options for treating mucormycosis. Expert Opinion on Orphan Drugs, 2016, 4, 1253-1261.	0.5	4
54	Use of a Commercial HIV Co-Receptor Tropism Assay in Clinical Practice. AIDS Patient Care and STDs, 2015, 29, 53-54.	1.1	1

#	ARTICLE	IF	CITATIONS
55	<i>In Vitro</i> Combination of Isavuconazole with Micafungin or Amphotericin B Deoxycholate against Medically Important Molds. Antimicrobial Agents and Chemotherapy, 2014, 58, 6934-6937.	1.4	39
56	Emerging drugs and vaccines for Candidemia. Mycoses, 2014, 57, 718-733.	1.8	31
57	Mold Infections of the Central Nervous System. New England Journal of Medicine, 2014, 371, 150-160.	13.9	157